Brief: Bergenbio Gets Approval To Commence Phase II Trial Of Bemcentinib For COVID-19 In South Africa

Oncoinvent ASA

11/09/2020 14:28

Sept 11 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * RECEIVES APPROVAL TO COMMENCE PHASE II TRIAL OF BEMCENTINIB FOR COVID-19 IN SOUTH AFRICA
    * TO PROCEED WITH A COMPANY SPONSORED PHASE II CLINICAL TRIAL TO ASSESS EFFICACY AND SAFETY
OF
BEMCENTINIB FOR TREATMENT OF COVID-19 IN HOSPITALISED PATIENTS
    * STUDY WILL ENROL 120 HOSPITALISED COVID-19 PATIENTS
    * BERGENBIO ALSO CONFIRMS IT IS IN LATE STAGE SET-UP PHASE TO EXPAND STUDY TO INCLUDE
ADDITIONAL
HOSPITAL SITES IN INDIA, AND EXPECTS TO BE IN A POSITION TO UPDATE MARKET IN NEAR FUTURE.
    * TRIAL PROTOCOL WILL PERMIT CO-ADMINISTRATION WITH OTHER MEDICINES RECOMMENDED FOR
TREATMENT OF
COVID-19, INCLUDING REMDESIVIR AND DEXAMETHASONE.

Source text for Eikon:  ID:nWkr8W24zt 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))